Literature DB >> 28082453

ATF3 expression in cardiomyocytes preserves homeostasis in the heart and controls peripheral glucose tolerance.

Roy Kalfon1, Lilach Koren1, Sharon Aviram1, Ortal Schwartz2, Tsonwin Hai3, Ami Aronheim4.   

Abstract

AIMS: Obesity and type 2 diabetes (T2D) trigger a harmful stress-induced cardiac remodeling process known as cardiomyopathy. These diseases represent a serious and widespread health problem in the Western world; however the underlying molecular basis is not clear. ATF3 is an 'immediate early' gene whose expression is highly and transiently induced in response to multiple stressors such as metabolic, oxidative, endoplasmic reticulum and inflammation, stressors that are involved in T2D cardiomyopathy. The role of ATF3 in diabetic cardiomyopathy is currently unknown. Our research has aimed to study the effect of ATF3 expression on cardiomyocytes, heart function and glucose homeostasis in an obesity-induced T2D mouse model. METHODS AND
RESULTS: We used wild type mice (WT) as well as mutant mice with a cardiac-specific ATF3 deficiency (ATF3-cKO). Mice were fed a high-fat diet (HFD) for 15 weeks. HFD induced high ATF3 expression in cardiomyocytes. Mice were examined for cardiac remodeling processes and the diabetic state was assessed. HFD-fed ATF3-cKO mice exhibited severe cardiac fibrosis, higher levels of heart hypertrophic markers, increased inflammation and worse cardiac function, as compared to WT mice. Interestingly, HFD-fed ATF3-cKO mice display increased hyperglycemia and reduced glucose tolerance, despite higher blood insulin levels, as compared to HFD-fed WT mice. Elevated levels of the cardiac inflammatory cytokines IL-6 and TNFα leading to impaired insulin signalling may partially explain the peripheral glucose intolerance.
CONCLUSIONS: Cardiac ATF3 has a protective role in dampening the HFD-induced cardiac remodeling processes. ATF3 exerts both local and systemic effects related to T2D-induced cardiomyopathy. This study provides a strong relationship between heart remodeling processes and blood glucose homeostasis. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Type 2 diabetes • Cardiac remodeling • Cytokines • High fat diet • ATF3

Mesh:

Substances:

Year:  2016        PMID: 28082453     DOI: 10.1093/cvr/cvw228

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  17 in total

1.  YAP Partially Reprograms Chromatin Accessibility to Directly Induce Adult Cardiogenesis In Vivo.

Authors:  Tanner O Monroe; Matthew C Hill; Yuka Morikawa; John P Leach; Todd Heallen; Shuyi Cao; Peter H L Krijger; Wouter de Laat; Xander H T Wehrens; George G Rodney; James F Martin
Journal:  Dev Cell       Date:  2019-02-14       Impact factor: 12.270

2.  Metabolic cardiomyopathies - fighting the next epidemic.

Authors:  Christoph Maack; Elizabeth Murphy
Journal:  Cardiovasc Res       Date:  2017-02-16       Impact factor: 10.787

3.  Putting the Brakes on Hypertensive Remodeling: An ATF3 Mechanism of Myofibroblast Restraint.

Authors:  Jennifer Davis
Journal:  Circulation       Date:  2017-05-23       Impact factor: 29.690

4.  Changes in Corticotrope Gene Expression Upon Increased Expression of Peptidylglycine α-Amidating Monooxygenase.

Authors:  Richard E Mains; Crysten Blaby-Haas; Bruce A Rheaume; Betty A Eipper
Journal:  Endocrinology       Date:  2018-07-01       Impact factor: 4.736

5.  Cardiomyocyte Cell-Cycle Regulation in Neonatal Large Mammals: Single Nucleus RNA-Sequencing Data Analysis via an Artificial-Intelligence-Based Pipeline.

Authors:  Thanh Nguyen; Yuhua Wei; Yuji Nakada; Yang Zhou; Jianyi Zhang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-04

6.  Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure.

Authors:  Jinliang Li; Yuliang Tan; Catherine L Passariello; Eliana C Martinez; Michael D Kritzer; Xueyi Li; Xiaofeng Li; Yang Li; Qian Yu; Kenneth Ohgi; Hrishikesh Thakur; John W MacArthur; Jan R Ivey; Y Joseph Woo; Craig A Emter; Kimberly Dodge-Kafka; Michael G Rosenfeld; Michael S Kapiloff
Journal:  Circulation       Date:  2020-09-16       Impact factor: 29.690

7.  Activating transcription factor 3 in immune response and metabolic regulation.

Authors:  Kavita Jadhav; Yanqiao Zhang
Journal:  Liver Res       Date:  2017-08-15

8.  Hepatocytic Activating Transcription Factor 3 Protects Against Steatohepatitis via Hepatocyte Nuclear Factor 4α.

Authors:  Yanyong Xu; Shuwei Hu; Kavita Jadhav; Yingdong Zhu; Xiaoli Pan; Fathima Cassim Bawa; Liya Yin; Yanqiao Zhang
Journal:  Diabetes       Date:  2021-09-02       Impact factor: 9.337

9.  Alternative oxidase-mediated respiration prevents lethal mitochondrial cardiomyopathy.

Authors:  Jayasimman Rajendran; Janne Purhonen; Saara Tegelberg; Olli-Pekka Smolander; Matthias Mörgelin; Jan Rozman; Valerie Gailus-Durner; Helmut Fuchs; Martin Hrabe de Angelis; Petri Auvinen; Eero Mervaala; Howard T Jacobs; Marten Szibor; Vineta Fellman; Jukka Kallijärvi
Journal:  EMBO Mol Med       Date:  2019-01       Impact factor: 12.137

10.  ATF3 Sustains IL-22-Induced STAT3 Phosphorylation to Maintain Mucosal Immunity Through Inhibiting Phosphatases.

Authors:  Doaa Glal; Janaki N Sudhakar; Hsueh-Han Lu; Ming-Che Liu; Hung-Yu Chiang; Yen-Chun Liu; Ching-Feng Cheng; Jr-Wen Shui
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.